Astria shareholders approve 5.5M share increase under 2015 plan, elect three directors

Astria Therapeutics, Inc.

Shareholders approved amendment adding 5,500,000 shares to the Second Amended and Restated 2015 Stock Incentive Plan (42.46M for, 7.68M against).
Jill C. Milne, Fred Callori, and Michael Kishbauch elected as Class I directors to three-year terms expiring at 2028 annual meeting.
Ernst & Young LLP ratified as independent auditor for fiscal 2025 (53.50M for, 53k against).
Advisory vote on named executive officer compensation passed (43.54M for, 6.61M against).

item 5.02item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.